Literature DB >> 15328135

Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.

Swati Pal1, Rajesh Ravindran, Nahid Ali.   

Abstract

In this work we report the activity seen with combination therapy using sodium antimony gluconate in liposomes composed of egg phosphatidyl choline and stearylamine for elimination of Leishmania donovani parasites from the liver and spleen of BALB/c mice with established and chronic infections.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15328135      PMCID： PMC514761          DOI： 10.1128/AAC.48.9.3591-3593.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  Novel methods for the encapsulation of meglumine antimoniate into liposomes.

Authors:  F Frézard; M S Michalick; C F Soares; C Demicheli
Journal:  Braz J Med Biol Res       Date:  2000-07       Impact factor: 2.590

2.  The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs.

Authors:  R L Juliano; D Stamp
Journal:  Biochem Biophys Res Commun       Date:  1975-04-07       Impact factor: 3.575

3.  Antileishmanial activity of antimonials entrapped in liposomes.

Authors:  R R New; M L Chance; S C Thomas; W Peters
Journal:  Nature       Date:  1978-03-02       Impact factor: 49.962

4.  Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs.

Authors:  C R Alving; E A Steck; W L Chapman; V B Waits; L D Hendricks; G M Swartz; W L Hanson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

5.  The use of Pentostam liposomes in the chemotherapy of experimental leishmaniasis.

Authors:  C D Black; G J Watson; R J Ward
Journal:  Trans R Soc Trop Med Hyg       Date:  1977       Impact factor: 2.184

6.  Control of the rate of hepatic uptake and catabolism of liposome-entrapped proteins injected into rats. Possible therapeutic applications.

Authors:  G Gregoriadis; D E Neerunjun
Journal:  Eur J Biochem       Date:  1974-08-15

7.  Interactions of liposomes with the reticuloendothelial system. II: Nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages.

Authors:  M J Hsu; R L Juliano
Journal:  Biochim Biophys Acta       Date:  1982-07-22

8.  Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.

Authors:  H Everlien; S Hockertz
Journal:  Arzneimittelforschung       Date:  1999-11

9.  Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

Authors:  C P Thakur; G P Sinha; A K Pandey; N Kumar; P Kumar; S M Hassan; S Narain; R K Roy
Journal:  Ann Trop Med Parasitol       Date:  1998-07

10.  Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India.

Authors:  T K Jha
Journal:  Trans R Soc Trop Med Hyg       Date:  1983       Impact factor: 2.184
View more
  8 in total

1.  Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.

Authors:  Roma Sinha; Jayeeta Roychoudhury; Partha Palit; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation.

Authors:  Antara Banerjee; Manjarika De; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

3.  Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis.

Authors:  Partha Palit; Abhijit Hazra; Arindam Maity; R S K Vijayan; Prabu Manoharan; Sukdeb Banerjee; Nirup B Mondal; Nanda Ghoshal; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

Review 4.  Liposomal drug delivery systems for the treatment of leishmaniasis.

Authors:  Felipe Francisco Tuon; Leticia Ramos Dantas; Regina Maia de Souza; Victoria Stadler Tasca Ribeiro; Valdir Sabbaga Amato
Journal:  Parasitol Res       Date:  2022-09-16       Impact factor: 2.383

Review 5.  Leishmaniasis treatment--a challenge that remains: a review.

Authors:  Dilvani O Santos; Carlos E R Coutinho; Maria F Madeira; Carolina G Bottino; Rodrigo T Vieira; Samara B Nascimento; Alice Bernardino; Saulo C Bourguignon; Suzana Corte-Real; Rosa T Pinho; Carlos Rangel Rodrigues; Helena C Castro
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

6.  Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice.

Authors:  Mahmoud R Jaafari; Neda Bavarsad; Bibi Sedigheh Fazly Bazzaz; Afshin Samiei; Dina Soroush; Serajodin Ghorbani; Mohammad M Lotfi Heravi; Ali Khamesipour
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

7.  Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.

Authors:  Jayeeta Roychoudhury; Roma Sinha; Nahid Ali
Journal:  PLoS One       Date:  2011-03-10       Impact factor: 3.240

8.  The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis.

Authors:  Luiz Filipe Gonçalves-Oliveira; Franklin Souza-Silva; Luzia Monteiro de Castro Côrtes; Laura Barral Veloso; Bernardo Acácio Santini Pereira; Lea Cysne-Finkelstein; Guilherme Curty Lechuga; Saulo Cabral Bourguignon; Fernando Almeida-Souza; Kátia da Silva Calabrese; Vitor Francisco Ferreira; Carlos Roberto Alves
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-08-12       Impact factor: 4.077
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.